GREAT POINT PARTNERS LLC
13F Reported Value
ⓘ$529.1M
incl. option notional
Equity Holdings
ⓘ$424.4M
Option Notional
ⓘ$104.7M
$46.3M puts / $58.4M calls
Holdings
42
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
GREAT POINT PARTNERS LLC disclosed 42 positions worth $529.1M in its Form 13F-HR for Q2 2026 — $424.4M in common stock plus $104.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) calls, followed by $VOR and $ABVX. During the quarter the fund opened 12 new positions and exited 12 — including a new stake in $ABVX and a full exit from $APGE. The portfolio is most concentrated in Healthcare (97.5% of disclosed assets). All figures are sourced directly from GREAT POINT PARTNERS LLC’s Form 13F-HR filing with the SEC under CIK 1281446.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$53.3M400,000 sh - —
Quality
$31.3M1,700,000 sh - —
Quality
$27.2M204,314 sh - 31.5
Quality
$26.3M3,000,800 sh - —
Quality
$25.8M600,836 sh - —
Quality
$24.9M4,215,930 sh - 7.1
Quality
$24.1M856,061 sh - —
Quality
$20.3M274,363 sh - 34.2
Quality
$20.0M600,000 sh - —
Quality
$20.0M425,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Abivax S.A.$ABVXCALL | — | $53.3M | 400,000 |
 Vor Biopharma Inc.$VOR | — | $31.3M | 1,700,000 |
| Abivax S.A.$ABVX | — | $27.2M | 204,314 |
 ImmunityBio, Inc.$IBRXPUT | 31.5 | $26.3M | 3,000,800 |
 Vera Therapeutics, Inc.$VERA | — | $25.8M | 600,836 |
 Zura Bio Ltd$ZURA | — | $24.9M | 4,215,930 |
 ALUMIS INC.$ALMS | 7.1 | $24.1M | 856,061 |
 Sol-Gel Technologies Ltd.$SLGL | — | $20.3M | 274,363 |
 Ultragenyx Pharmaceutical Inc.$RAREPUT | 34.2 | $20.0M | 600,000 |
 Definium Therapeutics, Inc.$DFTX | — | $20.0M | 425,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of GREAT POINT PARTNERS LLC's 42 positions.
Showing top 10 of 42 holdings.
Sector Allocation
Healthcare
$413.7M
Financials
$10.8M
Full Holdings — GREAT POINT PARTNERS LLC (Q2 2026)
All 42 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ABVXCALL | Abivax S.A. | $53.3M | — | NEW | — |
| 2 | $VOR | Vor Biopharma Inc. | $31.3M | 7.4% | -3% | — |
| 3 | $ABVX | Abivax S.A. | $27.2M | 6.4% | NEW | — |
| 4 | $IBRXPUT | ImmunityBio, Inc. | $26.3M | — | +0% | 31.5 |
| 5 | $VERA | Vera Therapeutics, Inc. | $25.8M | 6.1% | +201% | — |
| 6 | $ZURA | Zura Bio Ltd | $24.9M | 5.9% | +0% | — |
| 7 | $ALMS | ALUMIS INC. | $24.1M | 5.7% | +0% | 7.1 |
| 8 | $SLGL | Sol-Gel Technologies Ltd. | $20.3M | 4.8% | +0% | — |
| 9 | $RAREPUT | Ultragenyx Pharmaceutical Inc. | $20.0M | — | NEW | 34.2 |
| 10 | $DFTX | Definium Therapeutics, Inc. | $20.0M | 4.7% | NEW | — |
| 11 |  $ANNX | Annexon, Inc. | $20.0M | 4.7% | +40% | — |
| 12 |  $ORKA | Oruka Therapeutics, Inc. | $17.4M | 4.1% | +0% | — |
| 13 |  $MLTX | MoonLake Immunotherapeutics | $16.7M | 3.9% | +71% | — |
| 14 |  $SGMT | Sagimet Biosciences Inc. | $15.7M | 3.7% | NEW | — |
| 15 |  $CTNM | Contineum Therapeutics, Inc. | $15.1M | 3.6% | +15% | — |
| 16 |  $IMMX | Immix Biopharma, Inc. | $13.2M | 3.1% | +265% | — |
| 17 |  $CLYM | Climb Bio, Inc. | $13.0M | 3.1% | -25% | — |
| 18 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $12.6M | 3.0% | -60% | 8.7 |
| 19 |  $NKTR | NEKTAR THERAPEUTICS | $12.2M | 2.9% | -45% | 9.7 |
| 20 |  $NGNE | Neurogene Inc. | $11.1M | 2.6% | -30% | 27.4 |
| 21 |  $LBRX | LB PHARMACEUTICALS INC | $10.3M | 2.4% | +6% | — |
| 22 |  $IRD | Opus Genetics, Inc. | $8.1M | 1.9% | +507% | — |
| 23 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $7.9M | 1.9% | +0% | — |
| 24 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $7.7M | 1.8% | -50% | — |
| 25 |  $IFRX | InflaRx N.V. | $6.8M | 1.6% | NEW | — |
| 26 |  $RLMD | RELMADA THERAPEUTICS, INC. | $5.8M | 1.4% | +0% | — |
| 27 |  $JATT | JATT II Acquisition Corp. | $5.7M | 1.3% | NEW | — |
| 28 |  $CGEM | Cullinan Therapeutics, Inc. | $5.5M | 1.3% | +0% | — |
| 29 |  $ALT | Altimmune, Inc. | $5.3M | 1.3% | NEW | 8 |
| 30 |  $AMAN | Amanat Acquisition Corp. | $5.1M | 1.2% | NEW | — |
| 31 |  $RZLT | Rezolute, Inc. | $4.9M | 1.2% | +0% | — |
| 32 |  $SLN | Silence Therapeutics plc | $4.9M | 1.2% | -56% | — |
| 33 |  $PALI | PALISADE BIO, INC. | $4.8M | 1.1% | -33% | — |
| 34 |  $EVMN | Evommune, Inc. | $4.3M | 1.0% | +0% | 14.9 |
| 35 |  $SCYX | SCYNEXIS INC | $3.8M | 0.9% | -88% | — |
| 36 |  $GALTCALL | GALECTIN THERAPEUTICS INC | $3.7M | — | +0% | — |
| 37 |  $ELVN | Enliven Therapeutics, Inc. | $3.6M | 0.8% | NEW | — |
| 38 |  $HUMA | Humacyte, Inc. | $2.9M | 0.7% | +0% | 9.1 |
| 39 |  $RNTX | Rein Therapeutics, Inc. | $2.7M | 0.6% | NEW | — |
| 40 |  $DBVT | DBV Technologies S.A. | $2.6M | 0.6% | NEW | — |
| 41 |  $AVXLCALL | ANAVEX LIFE SCIENCES CORP. | $1.4M | — | +0% | 24.6 |
| 42 |  $PMN | ProMIS Neurosciences Inc. | $1.1M | 0.3% | -77% | — |
New Positions (12)
$ABVXCALL Abivax S.A.$53.3M$ABVX Abivax S.A.$27.2M$RAREPUT Ultragenyx Pharmaceutical Inc.$20.0M$DFTX Definium Therapeutics, Inc.$20.0M$SGMT Sagimet Biosciences Inc.$15.7M$IFRX InflaRx N.V.$6.8M$JATT JATT II Acquisition Corp.$5.7M$ALT Altimmune, Inc.$5.3M$AMAN Amanat Acquisition Corp.$5.1M$ELVN Enliven Therapeutics, Inc.$3.6M$RNTX Rein Therapeutics, Inc.$2.7M$DBVT DBV Technologies S.A.$2.6MExited Positions (12)
$APGE Apogee Therapeutics, Inc.
$KALV KalVista Pharmaceuticals, Inc.
$IMVT Immunovant, Inc.
$JBIO Jade Biosciences, Inc.
$ZBIO Zenas BioPharma, Inc.
$CMPX Compass Therapeutics, Inc.
$CNTX Context Therapeutics Inc.
$UNCY Unicycive Therapeutics, Inc.
$TENX TENAX THERAPEUTICS, INC.
$PHVS Pharvaris N.V.
$AVTX Avalo Therapeutics, Inc.
$ALKS Alkermes plc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for GREAT POINT PARTNERS LLC including:
Track GREAT POINT PARTNERS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for GREAT POINT PARTNERS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: GREAT POINT PARTNERS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For GREAT POINT PARTNERS LLC (SEC CIK: 1281446), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in GREAT POINT PARTNERS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.